U.S. Markets closed
  • S&P 500

    3,699.12
    +32.40 (+0.88%)
     
  • Dow 30

    30,218.26
    +248.74 (+0.83%)
     
  • Nasdaq

    12,464.23
    +87.05 (+0.70%)
     
  • Russell 2000

    1,892.45
    +43.75 (+2.37%)
     
  • Crude Oil

    46.09
    +0.45 (+0.99%)
     
  • Gold

    1,842.00
    +0.90 (+0.05%)
     
  • Silver

    24.32
    +0.18 (+0.76%)
     
  • EUR/USD

    1.2127
    -0.0022 (-0.1819%)
     
  • 10-Yr Bond

    0.9690
    +0.0490 (+5.33%)
     
  • Vix

    20.79
    -0.49 (-2.30%)
     
  • GBP/USD

    1.3438
    -0.0015 (-0.1088%)
     
  • USD/JPY

    104.1400
    +0.2800 (+0.2696%)
     
  • BTC-USD

    18,810.01
    -148.01 (-0.78%)
     
  • CMC Crypto 200

    367.86
    -11.38 (-3.00%)
     
  • FTSE 100

    6,550.23
    +59.96 (+0.92%)
     
  • Nikkei 225

    26,751.24
    -58.13 (-0.22%)
     

Company Profile for Atara Biotherapeutics, Inc.

·1 min read

Atara Biotherapeutics, Inc. is a leading off-the-shelf, allogeneic T-cell immunotherapy company developing novel treatments for patients with cancer, autoimmune and viral diseases. Atara’s technology platform leverages research collaborations with leading academic institutions with the Company’s scientific, clinical, regulatory and manufacturing expertise. Atara’s pipeline includes tab-cel® (tabelecleucel), which is in Phase 3 development for patients with Epstein-Barr virus-associated post-transplant lymphoproliferative disease (EBV+ PTLD) as well as in earlier stage development for other EBV-associated hematologic malignancies and solid tumors, including nasopharyngeal carcinoma (NPC); T-cell immunotherapies targeting EBV antigens believed to be important for the potential treatment of multiple sclerosis; and next-generation chimeric antigen receptor T-cell (CAR T) immunotherapies. The Company was founded in 2012 and is co-located in South San Francisco and Southern California. Our Southern California hub is anchored by our state-of-the-art manufacturing facility in Thousand Oaks, California. For additional information about the Company, please visit atarabio.com.

Company:

Atara Biotherapeutics, Inc.

Headquarters Address:

611 Gateway Blvd

Suite 900

South San Francisco, CA 94080

Main Telephone:

(650) 278-8930

Website:

https://www.atarabio.com/

Ticker:

ATRA (NASDAQ)

Type of Organization:

Public

Industry:

Biotechnology

Key Executives:

CEO: Pascal Touchon

CFO: Utpal Koppikar

COO: Joe Newell

Investor Relations

Contact:

John Craighead

Phone:

650-410-3012

Email:

jcraighead@atarabio.com

Public Relations

Contact:

Kerry Beth Daly

Phone:

516-982-9328

Email:

kdaly@atarabio.com

Investor Relations

Contact:

Susanna Chau

Phone:

650-477-8024

Email:

schau@atarabio.com

View source version on businesswire.com: https://www.businesswire.com/news/home/20200402005244/en/